Table 2.

Efficacy and toxicities of oral selective estrogen receptor degraders (SERDs) in development

Drug candidate	Clinical benefit rate	Mean degradation in patient	Select treatment-related adverse event (5% of patients)					CDK4/6i pretreated patients (0–100%)
			Gastrointestinal (GI) AEs			Other AEs
			Diarrhea	Nausea	Vomiting	Bradycardia	Visual disturbance
Elacestrant	42.6%	Not reported		√	√			100%
H38-65,545	34%	Not reported	√	√	√	√		87%
ZN-C5	40%	Not reported	√	√	√			87%
Rintodestrant	30%	28%	√	√	√			70%
SAR439859	34%	Not reported	√	√	√			63%
AZD9833	35%	< 50%		√	√	√	√	62%
GDC9545	41%	< 50%	√	√		√		59%

AEs, adverse effect; CDK 4/6i, cyclin-dependent kinase 4/6 inhibitor; SERDs, selective estrogen receptor degraders